Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPGx-RDH12 in Leber Congenital Amaurosis with RDH12 Mutations
NCT07681778Phase 2Recruiting
- Sponsor
- Opus Genetics
- Start
- Oct 2026
- Primary completion
- Dec 2032
- Countries
- 1
01
Overview
A Phase 2 trial of OPGx-RDH12 in Leber congenital amaurosis (LCA), sponsored by Opus Genetics. Started Oct 2026; status: recruiting.
02
Drugs
OPGx-RDH12
03
Conditions
Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on NCT07681778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07681778.